Site News  |   Monitor Keywords  |   Monitor Archive  |   Organizer  |   Account Info  |

Non-basic melanin concentrating hormone receptor-1 antagonists and methods

Non-basic melanin concentrating hormone receptor-1 antagonists and methods description/claims

The present invention relates to non-basic melanin concentrating hormone receptor-1 (MCHR1) antagonists, pharmaceutical compositions containing MCHR1 antagonists and methods of treating diabetes, obesity and related diseases employing such MCHR1 antagonists.

Several lines of pharmacological and genetic evidence support the role of Melanin Concentrating Hormone Receptor-1 (hereafter “MCHR1”) as a modulator of food intake and body weight. Central administration of melanin concentrating hormone (MCH) increases food intake and body weight both in rats and in mice. Chronic ICV infusion of MCH causes increased food intake and ultimately obesity in mice, while infusion of an MCH peptide antagonist blocks MCH-induced food intake and results in weight loss and decreased feeding in diet-induced obese mice.

The expression of both the MCH peptide and receptor are modulated by nutritional status. MCH mRNA is upregulated both in hyperphagic obese mice (ob/ob), and fasted animals. Targeted disruption of the gene for MCH peptide results in hypophagia and leanness. Disruption of the MCHR1 gene causes leanness, altered metabolism, and hyperlocomotion accompanied by mild hyperphagia. Conversely, over-expression of MCH peptide results in hyperphagia, obesity and diabetes. Small molecule MCHR1 antagonists have been shown to cause weight loss in rodent weight and feeding models after both oral and intraperitoneal administration; Eur. J. Pharmacol., 438:129-135 (2002), Nat. Med., 8:825-830 (2002), Eur. J. Pharmacol., 497:41-47 (2004).

Numerous non-peptide MCHR1 antagonists have been disclosed. The scope of the genus for each reflects a common perception regarding the criteria required for ligand recognition as MCHR1 agonists. A recent review of MCHR1 patent disclosures emphasized the commonality of these structures by the following description; “Ubiquitous throughout the MCH patent literature are molecules consisting of a central scaffold to which linkers to an aryl or heteroaryl group and a basic amino functionality are attached.” (Kowalski, T. J. et al., Expert Opin. Investig. Drugs, 13:1113-1122 (2004)). Pharmacophore models of these geni consistently envision a presumed prerequisite electrostatic interaction between a basic amine center of the antagonist ligand and aspartic acid 123 of the receptor which presumably is envisaged to emulate the mandatory interaction between arginine 14 of MCH peptide agonists with aspartic acid 123 of the MCHR1 receptor. (Ulven, T., J. Med. Chem., 48:5684-5697 (2005)) However, incorporation of this basic amine in a MCHR1 antagonist increases substantially the probability of binding to off-target ion-channels and biogenic amine receptors.

In accordance with the present invention, there is provided a series of novel high affinity selective MCHR1 antagonists for which binding affinity is not dependent upon inclusion of a basic amine functionality that is common to most of the disclosed MCHR antagonists. As a consequence, the absence of the basic center greatly reduces the probability of off-target interactions such as binding to other biogenic amine receptors as well as binding to ion channels such as the HERG receptor in the heart. The reduction/abolition of affinity for the HERG receptor is especially important since ligand occupancy is associated with initiation of fatal arrhythmias.

In one embodiment of the present invention, a compound of the Formula I or a pharmaceutically acceptable salt thereof is provided

wherein

is a phenylene ring or a heteroaryl ring which is a monocyclic ring or a bicyclic ring which contains one or two nitrogen atoms or one oxygen atom;

R1 is Z-Y—X—, wherein

Continue reading about Non-basic melanin concentrating hormone receptor-1 antagonists and methods...
Full patent description for Non-basic melanin concentrating hormone receptor-1 antagonists and methods

Brief Patent Description - Full Patent Description - Patent Application Claims

Click on the above for other options relating to this Non-basic melanin concentrating hormone receptor-1 antagonists and methods patent application.

Patent Applications in related categories:

20090286724 - Aggregable glp-1 analogue and sustained-release pharmaceutical composition - The present invention provides a GLP-1 analogue having a high association-aggregability or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition to be used for preventing or treating diabetes, hyperglycemia, a diabetic complication caused by diabetes or hyperglycemia, or obesity, using the same. ...

20090286722 - Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function - Peptide analogues and methods are provided for treating age-related symptoms of decreased pancreatic beta-cell function, including glucose intolerance, type 2 diabetes, beta-cell glucose insensitivity, insulin resistance and reduced insulin secretion. ...

20090286736 - Anti-inflammatory compounds and uses thereof - The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell. ...

20090286732 - Compounds for delivery of therapeutic and imaging moieties to nerve cells - where B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; M is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell, and can be a therapeutic moiety or an ...

20090286727 - Dp-78-like nanobodies - The present invention relates to Nanobodies® that have a high degree of sequence homology with human variable domain sequences from the VH4 class and in particular with human DP-78 sequences, polypeptides containing such Nanobodies®, nucleic acids encoding such Nanobodies® and polypeptides, and uses thereof. ...

20090286729 - Epidermal growth factor receptor antagonists and methods of use - The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity ...

20090286723 - Hybrid polypeptides with selectable properties - The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are ...

20090286733 - Long-acting veterinary polypeptides and methods of producing and administering same - A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed. ...

20090286735 - Method for administering glp-1 molecules - The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention. ...

20090286731 - Methods and compositions for the treatment of xerostomia - Methods for the treatment of xerostomia are described, hi particular, the present invention takes advantage of the inventors' observation that xerostomia is caused by induction of apoptosis, and can be inhibited by interfering with the cellular processes that trigger apoptosis in cells receiving chemo- and/or radiotherapy. ...

20090286725 - Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition - as well as the physiologically acceptable salts thereof. NR2R3, R2 and R3 being identical or different and denoting hydrogen or (C1-C10)-alkyl, X17 denotes OR1, ...

20090286734 - Pharmaceutical use of alpha antigen or alpha antigen gene - The α antigen-encoding gene and the α antigen protein suppress the production of interleukin-4 etc., improve the Th2 type cytokine-dominant state, and furthermore inhibit various conditions of allergic diseases such as IgE production, histamine release and eosinophil infiltration, and therefore they are very effective for the prevention or treatment of ...

20090286730 - Remedies for ischemia - The present invention relates to uses and methods of parathyroid hormone (PTH), preferably PTH (1-34), and/or parathyroid hormone-related peptide (PTHrP), preferably PTHrP (1-34), for recruiting stem cells into tissue suffering from ischemia, wherein said stem cells are preferably capable of repairing and/or regenerating said tissue suffering from ischemia. Accordingly, the ...

20090286721 - Targeted plasminogen activator fusion proteins as thromobolytic agents - This invention relates to novel fusion proteins, comprising a targeting protein and a plasminogen activator, preferably an antibody that binds to P-selectin, operably linked to the plasminogen activator DSPAalpha1, or analogs, fragments, derivatives, or variants thereof, which are useful as thrombolytic agents. Pharmaceutical compositions containing these fusion proteins, methods of ...

20090286728 - Tooth root formation promoting factors and method for promotion of tooth root formation - The present invention provides a tooth root formation promoting factor and a method for promotion of tooth root formation, which can promote tooth root formation and which are useful in various aspects of dental therapy. Specifically, the tooth root formation promoting factor contains, as an active ingredient, proteins belonging to ...

20090286726 - Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases - It is described the use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation. ...


###


How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Non-basic melanin concentrating hormone receptor-1 antagonists and methods or other areas of interest.
###


Previous Patent Application:
Method of treating parkinson's disease in humans by direct infusion of glial cell-line derived neurotrophic factor into the zona incerta
Next Patent Application:
Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis
Industry Class:
Drug, bio-affecting and body treating compositions

###

• Provisional Patent
• Utility Patent

• What Is a Patent?
• What Is a Trademark or Servicemark?
• What Is a Copyright?
• Patent Laws